Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.

[1]  M. Sorror,et al.  Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.

[2]  S. Yamasaki,et al.  Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  F. Awan,et al.  The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. , 2008, Blood.

[4]  C. Bredeson,et al.  81: Performance Status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), Predicts Mortality at a Canadian Transplant Centre , 2008 .

[5]  M. Sorror,et al.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.

[6]  W. Stock,et al.  Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS. , 2007 .

[7]  M. Aitchison,et al.  1120: Evaluation of an Inflammation Based Prognostic Score in Patients with Metastatic Renal Cancer , 2007 .

[8]  Burton H Singer,et al.  Combinations of biomarkers predictive of later life mortality , 2006, Proceedings of the National Academy of Sciences.

[9]  Sonali M. Smith,et al.  Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  D. McMillan,et al.  An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer , 2006, British Journal of Cancer.

[11]  Suzanne G. Leveille,et al.  Linking C-reactive protein to late-life disability in the National Health and Nutrition Examination Survey (NHANES) 1999-2002. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[12]  J. W. Lee,et al.  Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse , 2006, Bone Marrow Transplantation.

[13]  E. Holler,et al.  Evaluation of C‐reactive protein, interleukin‐6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients , 2006, European journal of haematology.

[14]  J. Bartlett,et al.  Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer , 2006, British Journal of Cancer.

[15]  C. Craddock,et al.  Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Esteve,et al.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.

[17]  S. Cummings,et al.  Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. , 2005, Journal of the American Society of Nephrology : JASN.

[18]  T. Zimmerman,et al.  Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[20]  J. Gribben,et al.  Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. , 2004, Blood.

[21]  E. Mariani,et al.  Peripheral blood markers of inflammation and functional impairment in elderly community-dwellers , 2004, Experimental Gerontology.

[22]  C. Flowers,et al.  Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. , 2004, Blood.

[23]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[24]  S. Rubin,et al.  Inflammatory Markers and Incident Mobility Limitation in the Elderly , 2004, Journal of the American Geriatrics Society.

[25]  T. Naoe,et al.  Allogeneic myeloablative transplantation for patients aged 50 years and over , 2004, Bone Marrow Transplantation.

[26]  Tamara B. Harris,et al.  The Associations Between Physical Activity and Inflammatory Markers in High‐Functioning Older Persons: MacArthur Studies of Successful Aging , 2003, Journal of the American Geriatrics Society.

[27]  R. Schots,et al.  Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation , 2003, Leukemia.

[28]  D. Levy,et al.  Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study , 2003, Circulation.

[29]  J. Sallis,et al.  American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. , 2003, Circulation.

[30]  R. Schots,et al.  An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation , 2002, Bone Marrow Transplantation.

[31]  L. Ferrucci,et al.  Peripheral Blood Markers of Inflammation Predict Mortality and Functional Decline in High‐Functioning Community‐Dwelling Older Persons , 2002, Journal of the American Geriatrics Society.

[32]  J. W. Lee,et al.  The kinetics of circulating cytokines including IL-6, TNF-α, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.

[33]  R. Harrup,et al.  Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.

[34]  J. Meis,et al.  Procalcitonin Does Not Discriminate Infection from Inflammation after Allogeneic Bone Marrow Transplantation , 2000, Clinical Diagnostic Laboratory Immunology.

[35]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[36]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[37]  Luigi Ferrucci,et al.  Serum IL‐6 Level and the Development of Disability in Older Persons , 1999, Journal of the American Geriatrics Society.

[38]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[39]  J. Filep,et al.  Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. , 1997, The Journal of clinical investigation.

[40]  G. Ciliberto,et al.  Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.

[41]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[42]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[43]  F. Appelbaum,et al.  A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation , 1993 .

[44]  J. Vossen,et al.  C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation , 1991, Infection.

[45]  P. Lansdorp,et al.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  I. Kushner,et al.  SERUM C‐REACTIVE PROTEIN LEVELS IN DISEASE * , 1982, Annals of the New York Academy of Sciences.

[47]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[48]  C. Bredeson,et al.  Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center , 2009, Bone Marrow Transplantation.

[49]  W. Stock,et al.  Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? , 2005, Leukemia.

[50]  P. Contu,et al.  Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients. , 2004, Oncology reports.

[51]  E. Keller,et al.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. , 2000, Annual review of medicine.

[52]  A. Markewitz,et al.  Detection of Acute Phase Response and Infection. The Role of Procalcitonin and C-Reactive Protein , 1999, Clinical chemistry and laboratory medicine.

[53]  G. Laurent,et al.  Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. , 1993, Blood.

[54]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[55]  D. Cox.  Regression Models and Life-Tables , 1972 .

[56]  R. Peto,et al.  Asymptotically efficient rank invariant test procedure (with discussion). , 1972 .